Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B
Open Access
- 1 February 2010
- journal article
- viral hepatitis
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 51 (6), 1945-1953
- https://doi.org/10.1002/hep.23568
Abstract
Approximately 30%-40% of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B treated with peginterferon and/or lamivudine achieve HBeAg seroconversion 6 months after the end of treatment. The durability and long-term effect of treatment are unknown. In this study, 85 HBeAg-positive patients who received peginterferon alfa-2b 1.5 μg/kg/week for 32 weeks and lamivudine 100 mg/day for 52 or 104 weeks were prospectively followed for 6.1 ± 1.7 years posttreatment. Twenty-five (29%) patients had virologic response (HBeAg seroconversion and HBV DNA P = 0.041]). At the last follow-up, the liver stiffness measurement by transient elastography was 5.8 ± 2.7 kPa. Only two patients had liver stiffness suggestive of advanced fibrosis. Week 16 HBV DNA, end-of-treatment HBeAg seroconversion, and undetectable HBV DNA were independent factors associated with virologic response at 5 years. The duration of concomitant lamivudine treatment had no impact on any long-term response. Conclusion: Peginterferon has high durability in HBeAg-positive chronic hepatitis B patients with end-of-treatment virologic response. (Hepatology 2010;)This publication has 36 references indexed in Scilit:
- Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2aGastroenterology, 2009
- Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapyHepatology, 2009
- Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patientsHepatology, 2008
- Hepatocellular Carcinoma and Hepatitis B VirusSeminars in Liver Disease, 2006
- Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferonAlimentary Pharmacology & Therapeutics, 2005
- Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis BHepatology, 2005
- Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis BThe New England Journal of Medicine, 2004
- Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis BHepatology, 2004
- Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantationJournal of Medical Virology, 2002
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995